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Abstract
The conservative management of upper tract urothelial carcinoma (UTUC) has historically been 
offered to patients with imperative indications. The recent International Consultation on Urologic 
Diseases publication on UTUC stratified treatment allocations based on high and low-risk groups. 
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The risk-stratified approach allows selective patients who could benefit from kidney preserving 
procedures (KPP) with oncological outcomes similar to radical nephroureterectomy (RNU) with 
bladder cuff excision. There are no prospective randomized controlled studies to support 
management guidelines. Recent developments in imaging, minimally invasive techniques, multi-
modality approaches, adjuvant topical and systemic chemotherapeutic regimens and bladder 
cancer prevention raise the hope for improved risk stratification and treatments with superior 
oncological outcomes.
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Introduction
Upper Tract Urothelial Carcinoma (UTUC) is a rare disease. Approximately two-thirds of 
UTUCs present as high-grade invasive disease at the time of diagnosis, and multifocal 
disease has been reported in about 25–30% of UTUCs [1, 2]. Radical nephroureterectomy 
(RNU) with excision of the bladder cuff is the gold standard surgical procedure for the 
treatment of UTUC in patients with a normal functional contralateral kidney with no 
evidence of metastatic disease [3]. The tumor characteristics can only be accurately 
determined by analysis of pathological specimens after RNU [4].
Low-risk cancers (defined for this section as pT0/pTa/pTis/pT1 low grade tumors) are 
reported in approximately 40–56% of UTUCs that undergo RNU, which may represent 
patients amenable to kidney preserving procedure (KPP) such as endoscopic management 
(ureteroscopic or percutaneous approach), partial nephrectomy and segmental ureterectomy 
[5, 6].
The management of UTUC should attempt to stratify patients in a pre-operative setting, 
allowing identification of individuals who may benefit from conservative kidney preserving 
procedures (KPP) without compromising oncological outcomes while preserving renal 
function [7]. Several studies have reported KPP for the treatment of low-risk UTUC in 
selected patients, suggesting similar oncological outcomes as the gold standard RNU [8]. 
This stratification can be performed using various prognostic factors that have been shown to 
be predictive of outcomes in multiple studies [9].
The KPP approach in the management of UTUC has been offered to patients with normal 
contralateral renal function, for low risk tumors as defined above, including selective cases 
of carcinoma in-situ (CIS) or high-grade presumed noninvasive tumors. Conservative 
approaches can also be considered in imperative cases in those with renal insufficiency, 
bilateral UTUC, solitary kidney and associated severe morbid conditions that preclude 
fitness for surgery [10]. Strict surveillance is a prerequisite for follow-up after KPP allowing 
detection of recurrence and disease progression. The focus of this review is to provide an 
overview of the current indications and modalities of KPP in the management of low-risk 
UTUC, and assessing the recommendations based on the level of evidence and grade of 
recommendations.
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Endoscopic treatment of low-risk UTUC
The objectives of the endoscopic management of low-risk UTUC are to control local tumor 
growth, prevent local recurrence and disease progression while preserving the renal function 
in selected patients. The endoscopic management of low-risk UTUC needs meticulous and 
stringent close follow-up due to limitations of clinical staging with ureteroscopic biopsy, 
imaging studies and risk of high recurrence rates in these patients. There have been no 
prospective randomized studies comparing endoscopic management with RNU in support of 
the management guidelines. Most available published data to date is limited to retrospective 
or pooled retrospective data from selected institutes or case reports. These retrospective 
cohort studies would fall under the category of level 3-evidence. In a recent systematic 
review, a 52% recurrence of UTUC after endoscopic management and 37% recurrence was 
reported in percutaneous management [11]. Tumor grade, multifocality, tumor size, history 
of bladder cancer have been reported as predictors of UTUC recurrence [12]. Whether or not 
the addition of topical therapy can improve these recurrence rates remains a topic of some 
debate and is discussed further below.
Endoscopic management of UTUC is deemed a failure if clinical or radiological evidence of 
locally advanced or metastatic disease or pathological up staging or up grading is found on 
subsequent RNU specimen. Cutress et al. reported pooled data of failure rates for 
ureteroscopic treatment of around 24% and for the percutaneous approach around 32% [11]. 
A follow-up biopsy of the tumor base after ablation of the lesions might be helpful to 
determine if additional modalities of treatment are required (Table-1).
1. Diagnosis
1.1. Imaging
The Imaging modality identifying soft tissue density within the pelvicalyceal cavities and 
ureteral lumen has been most commonly used for the diagnosis of UTUC. CT urography 
(CTU) is a standard imaging study for the diagnosis of UTUC. Both nephrographic and 
excretory phases of CTU are complementary for the diagnosis of UTUC [13]. CTU using 
thin slices (<2mm) to visualize the entire urinary tract through multiplanar reformatted 
imaging (MPR) offers accuracy in diagnosing UTUC (Figure 1).
A filling defect or soft tissue density in the renal collecting system that enhances after the 
administration of contrast is highly suspicious for UTUC. CTU limitations leading to 
unclear findings might include flat lesions or focal wall thickening or sub-centimeter lesions 
for which attenuation measurements are difficult to characterize the lesion, or may be 
nonspecific findings [14]. A meta-analysis and systematic review of CTU for UTUC 
reported pooled sensitivity of 96% (95% CI, 88–100%) and specificity of 99% (95%CI, 98–
100%) [15]. Another systematic review showed similar high sensitivity and specificity for 
CTU (96 and 99%) and retrograde urography (96 and 96%) in detecting the UTUC [16].
MR-Urography (MRU) had a high specificity of 97% with a rather low sensitivity of 69% 
[1]. Excretory urography had a low specificity of 81% and low sensitivity of 80%. It has 
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been noted that sensitivities are lower with lower tumor burden for all imaging modalities 
[1].
1.2. Diagnostic Ureteroscopy (URS)
The development of high definition flexible fiber-optic and now digital URS has greatly 
improved visualizing the entire upper urinary tract and ureters. URS evaluation of UTUC 
should assess for tumor location, number, size, and architecture. URS assessment under 
direct vision of these parameters influences the treatment approach and outcomes. Ureteral 
access sheaths have been shown to increase the diagnostic efficacy of URS. Diagnostic URS 
should assess the ureter before the placement of ureteral access sheath. URS significantly 
missed concomitant CIS when compared to RNU specimens (9.7% vs. 43.3%) [17]. URS is 
invaluable in those cases where renal preservation may be paramount, such as individuals 
with renal insufficiency, solitary kidney, and multiple comorbidities. URS facilitates 
selective ureteral sampling for cytology from the renal pelvicalyceal system and ureters, 
which provides prognostic information. URS findings combining with biopsy grade, urinary/
selective cytology, and imaging findings may help in determining if the patient would 
benefit from endoscopic management of UTUC (Table-1). The accuracy of URS biopsies for 
diagnosis and grading of UTUC is summarized in Table-2.
1.3. Biopsy
The difficulties in predicting accurate clinical staging result from limitations in biopsy 
specimen size and restriction of depth of resection. The tumor grade of UTUC is thus a 
primary driver in making treatment decisions, as grade is used to infer stage. Low-grade 
disease on biopsy specimen has a positive predictive value of 80–90% in predicting low 
stage disease, while high-grade disease has lower predictive value for invasiveness. It is 
often helpful for the pathologist to have more than one biopsy since non-diagnostic tissue 
materials are found in URS biopsy specimens up to 25% to 31.5% [17, 24, 26].
The primary objective of tumor biopsy is obtaining a proper grade rather than adequate 
staging. About 68–100% of G1 tumors on biopsy are non-invasive on final histology while 
62–100% of G3 tumors are invasive. Results for G2 tumors vary significantly from 17–80%, 
again reflecting likely inclusion of both low and high-grade disease in this histological 
subgroup. Grade is one of the most important predictive factors for oncologic outcome of 
endoscopic treatment. High-grade UTUC has worse oncological outcomes. Gillan et al. in a 
retrospective multicenter study reported URS biopsy grade matched with final RNU 
histopathology on 43.4%, only 32.6% had concordance between URS biopsy and final 
pathology for both grade and stage of UTUC. Concomitant carcinoma in-situ (CIS) was 
found in 21.6% of cases in final RNU pathology, with finding of discordance between URS 
biopsy specimens and RNU specimens in the diagnosis of concomitant CIS in UTUC [17] 
(Table-1 and 3).
The multi-biopsy approach has been proposed to improve diagnosis. Biopsy grade was 
identical in 43.4% to 78% of cases to surgical pathology [17, 24]. The combined use of 
access sheath, cup biopsies, and baskets (particularly for papillary tumors) can yield 
substantially more tissue than has been historically possible (Figure 2).
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1.4. Cytology
Cytological examination is thought to play a significant role in diagnosis of high-grade 
urothelial cancer (UC) and CIS of the bladder, however, its role in the detection and 
management of UTUC is poorly investigated and controversy exists in the utility of routine 
cytology testing in the absence of radiographic or direct visual endoscopic evidence of a 
tumor. In cases where an upper tract source is suspected, selective ureteral samples (by 
catheterization or with brushing) are performed for lateralizing the source of the finding but 
should be confirmed endoscopically when possible. Recent interest in urinary biomarker 
studies for malignancies has developed [19]. The sensitivity of selective ureteral cytology for 
UTUC ranged from 43% to 78% [21, 27], with false-negative results as high as 50% for low-
grade neoplasms [13].
Messer et al. evaluated patients who had undergone RNU or distal ureterectomy without 
previous history of bladder cancer and concluded the positive urine cytology was not 
predictive of either muscle invasive disease or high-grade urothelial lesions [29]. Selective 
upper tract cytology was more frequently positive than voiding urine cytology (60.3% vs. 
33.6%, p<0.001). Sensitivity was 45.0% for low-grade UTUC, 66.3% for high-grade UTUC, 
and 78.6% for isolated CIS [15]. A multi-institutional retrospective study using Johns 
Hopkins Hospital template of cytopathology criteria reported sensitivity, specificity, PPV 
and NPV of UT urine cytology for high-grade UTUC were 71.4%, 91.9%, 66.7% and 93.4% 
respectively [31]. UT urine cytology has low sensitivity and specificity for low-grade UTUC 
[16–18].
The UroVysion test (Abbott Molecular, Des Plaines, IL, USA) is a multi-target multicolor 
fluorescent in situ hybridization (FISH) assay. This test has high occurrence of specific 
chromosomal abnormalities in urothelial cancers. UroVysion showed abnormalities in 91% 
of CIS and all invasive cancers and about 30% of nonneoplastic lesions in patients with 
concomitant urothelial carcinoma. The sensitivity of UroVysion ranges from 39 to 97% 
(average 74%) but is significantly lower for low-grade and low-stage tumors [19]. The 
UroVysion/fluorescent in-situ hybridization (FISH) combined with UT urine cytology may 
improve the sensitivity of detecting low grade-UTUC [35]. Table 1 shows the 
recommendations for cytology and markers.
2. Surgical Techniques
A Cochrane review of the surgical management of UTUC concluded that there is no high-
quality evidence available to determine the best surgical management [21].
2.1. Endoscopic treatment of low-risk UTUC
2.1.1 Ureteroscopic management—Digital flexible URS is a most valuable instrument 
to evaluate the intrarenal collecting system and ureter under direct vision that enables 
complete ablation of the tumor. Advanced laser technology using holmium, 
holmium:yttrium aluminum garnet (YAG) and the neodymium:YAG lasers are efficient for 
treating neoplasms and can be delivered through a flexible ureteroscope.
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The holmium:YAG laser energy tissue penetration is <0.5 mm, which enables excellent 
tumor ablation with a reduced risk of upper urinary tract perforation. The neodymium:YAG 
laser uses an alternative source of energy that has a tissue penetration of up to 5–6 mm and 
works by coagulative necrosis with eventual sloughing of the necrotic tumor. Laser 
technology for UTUC ablation through flexible URS has the advantage of lower morbidity 
compared to electrocautery. Other approaches include using a flat wire basket or tumor 
grasping forceps to debulk the tumor burden, with the tumor base treated with either 
electrocautery delivered through small Bugbee electrode (2 or 3 Fr) or laser ablation using 
flexible fibers (200 um or 365 um) that easily fit through the working channel of the URS 
[22, 23].
The outcomes of URS management of UTUC have been reported in various retrospective 
studies. The accuracy of URS grading is summarized in Table-2. URS management of 
UTUC can be associated with a high local recurrence (LR) and intravesical recurrence (IVR) 
rate. Table-3 shows these outcomes of URS management of UTUC.
2.1.2. Percutaneous management—The percutaneous antegrade approach can be 
considered for low-grade, large volume UTUCs that may not be anatomically accessible 
with flexible URS. After establishing percutaneous access, the tumor can be ablated using 
resectoscopes, cold cup biopsy forceps, or laser ablation. Percutaneous approach allows 
antegrade instillation of topical adjuvant agents if indicated after successful tumor ablation 
[45]. Retrospective studies have reported that the percutaneous approach had a lower local 
recurrence rates and lower IVR when compared to URS approach in the management of 
UTUC [46]. The oncological outcomes of the percutaneous approach in the management of 
UTUC are summarized in Table-4.
2.1.3. Adjuvant Topical Therapies
Recurrence rates in the upper tract following endoscopic treatment of UTUC have been 
reported in 30–70% of patients [68, 69]. Topical adjuvant agents might decrease the risk of 
local recurrence as suggested by several reported case series [57]. In theory, there should be 
a role of topical adjuvant therapies based on what is observed in patients with bladder cancer 
[9].
Adjuvant topical installation can be accomplished in either antegrade instillation through 
nephrostomy tube or retrograde instillation through an open-ended, multiple side hole 
ureteral catheter (Figure 3). Use of double-J stents promoting reflux is not a reliable delivery 
method and its use is discouraged.
Topical treatment of UTUC is made more complicated by the need for reliable approach of 
accessing the upper tract, mode of delivery, and lack of dwell time for the therapeutic agent. 
A single-institution retrospective study of 28 cases was recently presented, showing 
improved results of adjuvant topical chemotherapy to the upper tract when given as 
induction and maintenance therapy [60]. Lifshitz et al. recently reported a novel hydrogel 
polymer with reverse thermal gelation properties, solid at body temperature and liquid at 
cold temperature, which might promote high-dose delivery of Mitomycin C into the upper 
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urinary tract [61]. This product is expected to enter a phase 2/3 trial in the United States by 
2016 for intended use as chemoablation of low-grade UTUC.
Patients with high-grade non-invasive UTUC considered for conservative management 
should be offered adjuvant installation of BCG. For isolated CIS (Figure 4), in the absence 
of any papillary tumors, topical therapy should be considered the primary mode of 
treatment, given the field-effect nature of the disease. The available data pertaining to BCG 
instillation in patients with CIS is limited to small series of retrospective studies.
Patients with UTUC treated with RNU subsequently developed IVR in approximately 30% 
[9]. The risk of IVR is even greater in patients managed with KPP, and such patients might 
logically benefit from the adjuvant intravesical instillation of chemotherapy. Two 
randomized clinical trials have demonstrated a decreased risk of IVR after radical 
nephroureterectomy when using a single dose of early intravesical instillation of 
chemotherapy [71, 72]. Future studies are needed to evaluate the benefit of single dose 
intravesical chemotherapy after KPP.
2.2. Conservative Surgery
2.2.1. Partial pyelectomy or partial nephrectomy—Partial pyelectomy or partial 
nephrectomy is rarely performed for renal pelvic tumors, in particular with advent of newer 
digital URS technologies. Partial nephrectomy has a very narrow indication for treatment of 
UTUC and is rarely undertaken due to the uncommon nature of the disease as well as the 
much higher technical complexity than partial nephrectomy for parenchymal tumors (Figure 
5). Generally it is reserved for low-grade, unifocal polar tumors in the setting of solitary 
kidneys, and has had variably successful results [62].
2.2.2. Segmental ureterectomy—Ureteral cancers occur in the distal ureter about two-
thirds of the time, and these may be managed with endoscopic ablation or segmental 
resection with ureteroneocystostomy in highly selected patients. High risk proximal or mid 
ureteral tumors are managed with RNU with bladder cuff excision. For low risk tumors, 
these can invariably be managed endoscopically in most cases.
3. Follow-up
The European Association of Urology (EAU) guidelines recommend close oncological 
follow-up for ≥5 years [63]. After conservative management, cystoscopy, ureteroscopy and 
cytology at 3 and 6 months, and then every 6 months for 2 years, then yearly. Urinary 
cytology and CTU at 3 and 6 months, and then yearly.
Low-risk UC have a low risk of progression to invasion (<3%), metastasis and death, but 
often recur as non-invasive lesions elsewhere within the urinary tract [77, 78]. Five-year 
disease specific survival for pT0/pTa/pTis is 100% and pT1 92% respectively [4]. Noting 
that the majority of UTUC cases are high-grade [4], the greatest potential lies in improving 
clinical risk stratification, which is highly limited in this disease.
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3.1. Cystoscopy
IVR has been reported in 20–50% of patients after RNU for UTUC [10]. Recurrence is 
common within the first 2 years after the management of UTUC, thus strict follow-up with 
scheduled cystoscopic evaluation is prudent in detecting IVR [9].
3.2. Urinary cytology
Urine cytology preferably collected with selective washings might be helpful in assessing 
tumor recurrence after conservative treatment of low-risk UTUC.
3.3. Imaging
CTU is a standard imaging study for surveillance for early detection of potential recurrence 
following KPP approach for low-grade, low-stage UTUC. MRU is indicated in patients with 
renal insufficiency or allergic to iodinated based IV contrast media. However, gadolinium is 
contraindicated in patients with severe renal insufficiency (GFR <30 ml/min), although in 
these cases T2 weighted imaging without gadolinium may still be performed.
3.4. Ureteroscopy
Patients treated with KPP require close monitoring owing to the high risk of recurrence [1]. 
URS has become most valuable to evaluate these patients while assessing ipsilateral as well 
contralateral renal units for recurrence and selective collection of urine cytology.
Conclusions
The management of UTUC requires a risk-adopted approach, which determines who would 
benefit from KPP. This strategy has demonstrated oncological outcomes in selected patients, 
which appear to be comparable with gold standard RNU with bladder cuff excision in 
patients with low-risk UTUC, albeit only within the context of retrospective, single 
institutional data. Adjuvant topical therapies, particularly with novel agents, raise the hope 
of decreasing the risk of tumor recurrence and disease progression in those undergoing KPP. 
Recent developments in genomics, tumor biology, and molecular profiling of UTUCs hold 
promise in providing a better risk-adopted approach and development for future therapies.
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Figure 1. 
Sagittal view of a computed tomography scan showing a filling defect representing a soft 
tissue mass in the upper pole of the left collecting system, in a patient with prior endoscopic 
therapy for low grade left ureteral tumors. Biopsy in this case showed high grade papillary 
tumor. Nephroureterectomy showed parenchymal invasion (stage pT3).
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Figure 2. 
Photographs showing biopsy tools and potential specimen sizes. A) cup biopsy forceps and 
coaxial 3-way prong; B) steel-wire basket.
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Figure 3. 
Figures showing our institutional technique for reliably instilling topical therapy to the upper 
tract by either nephrostomy tube or cystoscopically placed Beacon tip ureteral catheter. 
Patients are given the option of technique employed in the absence of data for the better 
technique.
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Figure 4. 
Photomicrograph showing upper tract carcinoma in-situ. Original magnification 200x.
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Figure 5. 
A partial nephrectomy specimen performed in a patient with a solitary kidney and polar 
tumor (T). Blue ink indicates the urothelial margin. As opposed to partial nephrectomy for 
parenchymal tumors, the urothelial margin needs to be planned and examined in addition 
when performing a partial nephrectomy for UTUC. Indications for partial nephrectomy are 
very narrow, and include an endoscopically unmanageable tumor, no multifocality, polar 
location, and imperative indications for kidney preservation.
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Table 1
Recommendations for diagnosis and management of low risk tumors.
Recommendations for endoscopic management LEV GOR
Unifocal 3 B
Small lesions (<2cm) 3 C
Low-grade tumor on biopsy 3 B
Negative cytology 3 C
Complete visualization 3 B
Papillary tumor 3 B
Good compliance 3 B
Understanding of invasive and close follow-up 3 B
All other tumor or patients features should be treated only in very selected patients with endoscopic treatment 
Recommendations for imaging
3 B
Imaging should be performed for exclusion of endoscopic treatment 3 B
CT-Urography should be performed for staging 3 B
Retrograde urography should be performed during endoscopic evaluation 3 C
Recommendations for diagnostic ureteroscopy
Ureteroscopic inspection of UTUC alone, without biopsy, has a very limited role, thus, biopsies are recommended 3 B
Tumor architecture, multifocality, number of lesions, size of lesions and their localizations should be documented 3 C
Localizations should also be evaluated for accessibility (need for flexible ureteroscopy, percutaneous approach) 3 C
Cystoscopy should be performed to exclude bladder cancer (up to 15%) 3 B
Recommendations for biopsy
Retrograde pyelography should be performed 3 C
Ureteroscopy should be performed 3 B
Flexible Ureteroscopy has technical advantages, especially for performing biopsies 3 C
The percutaneous approach is reserved for special indications 3 B
The biopsy can be performed using cup biopsies or using the basket 3 C
Ureteroscopic biopsy should be performed before endoscopic treatment 3 C
Number of biopsies should be more than 1 3 C
Biopsy should distinguish between low and high-grade tumors 3 B
Grade is a surrogate marker. G1 correlates with low grade and low stage disease, whereas high grade correlates with high 
grade and high stage disease.
3 B
G2 alone is insufficient for the decision of endoscopic treatment, especially in elective cases. 3 B
The use of access sheets should be avoided during diagnostic approach 4 C
Recommendations for cytology and markers
Malignant tumor cells on urinary cytology suggest high grade / CIS disease 3 B
Cytology should be performed, because it can add information for decision making, however, voiding voided cytology is of 
little value.
3 C
Selective cytology from the upper tract should be considered to detect high grade and CIS 3 B
Urine markers like fluorescence in situ hybridization can increase sensitivity in experienced hands 3 C
Cytology should be done before using contrast agents and instrumentation because manipulation can lead to erroneous results 3 B
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LEV = Level of evidence; GOR = Grade of recommendation
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Table 2
Accuracy of grading in ureteroscopic biopsies during diagnosis of UTUC
Author No. of UTUC cases 
(n)
No. of biopsies diagnostic 
(%)
No. Grading Correct (%) No. of upgraded tumors
Gillan et al. 2015 [17] 92 30 (32.6%) 40 (43.4%) 11 (11.9%)
Vashistha et al. 2013 [18] 43 32 (74%) 27/31 (87%) 3/31 (9.7%)
Wang et al., 2012 [19] 184 48 (26%) 83 (45%) 23 (96%)
Smith et al., 2011 [20] 65 NR 41 (63%) 24 (43%)
Williams et al., 2008 [21] 30 30 (100%) 17 (56.7%) 3 (50%)
Shirashi et al., 2003 [22] 40 35 (87.5%) 18 (58%) 0 (0%)
Skolarikos et al., 2003 [23] 62 51 (82%) 35 (69%) NR
Guarnizo et al., 2000 [24] 45 40 (89%) 31(78%) 5 (19%)
Keeley et al., 1997 [25] 51 42 (82.4%) 38 (90%) 10%
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Table 3
Outcomes of series using ureteroscopic treatment for UTUC
Study Number of patients mean/median FU (months) Recurrence (%) OS (%) CSS (%) KPR (%)
LR / IVR
Hoffman et al 2014 [39] 25 26 36/44 100 100 100
Fajkovic et al., 2013 [5] 20 20 25 / 15 45 95 100
Cutress et al., 2012 [40] 73 54 68 / 53 60 90 81
Grasso et al., 2012 [41] 66 51.5 77 / 61 74 87 83
Gadzinski et al., 2010 [42] 34 58 84 / NR 75 100 89
Cornu et al., 2010 [43] 35 24 60 / 40 100 100 89
Pak et al., 2009 [44] 57 53 90 / NR 93 95 81
Lucas et al., 2008 [45] 39 33 46 / NR 62 82 72
Painter et al., 2008 [46] 45 NR NR / NR NR 89 91
Krambeck et al., 2007 [47] 37 32 62 / 37 35 70 70
Reisiger et al., 2007 [48] 10 73 50 / 70 100 100 90
Roupret et al., 2006 [49] 27 52 15 / 22 77 81 74
Johnson et al., 2005 [50] 35 32 68 / NR NR 100 97
Iborra et al., 2003 [51] 23 NR 35 / NR NR 96 91
Matsuoka et al., 2003 [52] 26 33 26 / 15 NR 89 NR
Daneshmand et al., 2003 [53] 30 31 90 / 23 77 97 87
Chen et al., 2001 [54] 23 30 64 / 12 NR NR NR
Engelmyer et al., 1996 [55] 10 43 70 / NR 90 100 100
Gaboardi et al., 1994 [56] 18 15 50 / NR 100 100 94
Andersen et al., 1994 [2] 10 25 NR / NR NR NR 80
Schmeller et al., 1989 [57] 16 14 19 / NR 100 100 100
Abbreviations: CSS, cancer-specific survival; IVR, intravesical recurrence; NR, not reported; OS, overall survival; RNU, radical nephroureterectomy; LR, local recurrence; KPR, kidney preserving rate.
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Table 4
Outcomes of series using percutaneous approach for UTUC
Study Number of patients mean FU (months) Recurrence (%) OS (%) CSS (%) KPR (%)
LR /IVR
Motamedinia et al. 2015 [60] 141 66 37 LG, 63
HG/NR
NR NR 87
Rastinehad et al., 2009 [58] 89 61 33 / NR 68 Nr 87
Roupret et al., 2007 [61] 24 62 13 / 17 79 83 79
median
Palou et el., 2004 [59] 34 51 44 / NR 74 94 74
Goel et al., 2003 [62] 20 64 65 / 15 NR 75 50
Clark et al., 1999 [63] 17 24 33 / NR 75 82 88
Patel et al., 1996 [64] 26 45 35 / 42 75 91 94
Plancke et al., 1995 [65] 10 28 10/NR 90 100 90
Fuglsig et al., 1995 [66] 26 21 31 / NR 96 100 65
Tasca et al., 1992 [67] 10 19 50 / NR 90 100 70
Abbreviations: CSS, cancer-specific survival; IVR, intravesical recurrence; NR, not reported; OS, overall survival; RNU, radical nephroureterectomy; LR, local recurrence; KPR, kidney preserving rate.
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